Table 1 Baseline characteristics of patients requiring repeat plasma CMV viral load testing

Age (years) [median (IQR)]

55 (38–68)

60 (47–71)

0.001

Male gender [n (%)]

154 (52.9)

144 (45.3)

0.060

Ward

0.032

 General ward [n (%)]

206 (70.8)

199 (62.6)

 Intensive care unit [n (%)]

85 (29.2)

119 (37.4)

Comorbidities [n (%)]

271 (93.1)

298 (93.7)

0.772

Solid organ transplantation [n (%)]

74 (25.4)

39 (12.3)

< 0.001

 Kidney

67 (90.5)

36 (92.3)

 Liver

4 (5.4)

0 (0.0)

 Heart

3 (4.0)

3 (7.7)

HSCT [n (%)]

21 (7.2)

25 (7.9)

0.763

 ASCT

7 (33.3)

3 (12.0)

 MSD

6 (28.6)

11 (44.0)

 MUD

8 (38.1)

9 (36.0)

 MMD

0 (0.0)

2 (8.0)

 Patients with GVHD

4 (19.1)

11 (44.0)

Autoimmune diseases [n (%)]

62 (21.3)

66 (20.8)

0.868

 SLE

29 (46.8)

24 (36.4)

 Systemic vasculitides

6 (9.7)

7 (10.6)

 Rheumatoid arthritis

5 (8.1)

3 (4.5)

 Inflammatory myositis

1 (1.6)

6 (9.1)

 Systemic sclerosis

4 (6.5)

4 (6.1)

Leukemia [n (%)]

39 (13.4)

32 (10.1)

0.200

Lymphoma [n (%)]

24 (8.3)

28 (8.8)

0.806

Solid malignancy [n (%)]

14 (4.8)

7 (2.2)

0.078

HIV [n (%)]

13 (4.5)

8 (2.5)

0.187

COVID-19 [n (%)]

0 (0.0)

69 (21.7)

 < 0.001

Pretransplant CMV IgG in HSCT patients [n (%)]

0.261

 Unavailable

16 (76.2)

16 (64.0)

 D + /R + 

4 (19.1)

9 (36.0)

 D + /R-

1 (4.8)

0 (0.0)

Pretransplant CMV IgG status in solid organ transplant patients [n (%)]

0.717

 Unavailable

14 (18.9)

4 (10.3)

 D + /R + 

55 (74.3)

33 (84.6)

 D + /R-

3 (4.1)

2 (5.1)

 D-/R + 

1 (1.4)

0 (0.0)

 D-/R-

1 (1.4)

0 (0.0)

Immunosuppressive used [n (%)]

 Corticosteroid

160 (55.0)

181 (56.9)

0.631

 Prednisolone > 20 mg/day

79 (27.2)

124 (39.0)

0.002

 Tacrolimus

54 (18.6)

34 (10.7)

0.006

 Cyclosporin

33 (11.3)

27 (8.5)

0.239

 Cyclophosphamide

28 (9.6)

21 (6.6)

0.171

 Mycophenolic acid

65 (22.3)

50 (15.7)

0.037

 mTOR inhibitor

8 (2.8)

2 (5.2)

0.054

 Antithymocyte globulin

17 (5.8)

14 (4.4)

0.420